REGN Regeneron Pharmaceuticals, Inc.
Price Chart
Executive Summary
Regeneron and Sanofi announced European Commission approval of Dupixent for children aged 2 to 11 years with moderate-to-severe chronic spontaneous urticaria (CSU), expanding its label to younger patients. This marks the first targeted therapy for this age group in the EU and strengthens Dupixent's position in type 2 inflammation-driven diseases.
Actionable Insight
This approval strengthens Dupixent's dominance in type 2 inflammation markets and supports future U.S. approval prospects. Traders should monitor the FDA decision on the sBLA for pediatric CSU, which could further expand commercial reach. Despite recent insider selling, the clinical and regulatory momentum supports continued premium valuation.
Key Facts
- European Commission approved Dupixent for children 2 to 11 years with CSU who are unresponsive to antihistamines and naïve to anti-IgE therapy.
- Approval based on LIBERTY-CUPID trial program, including extrapolated adult efficacy data and pediatric safety/efficacy from CUPIDKids trial.
- Dupixent is now approved for children under 12 across four chronic type 2 inflammatory diseases.
- U.S. supplemental Biologics License Application (sBLA) for this population is under review.
Financial Impact
Expands Dupixent's eligible patient population in the EU, increasing long-term revenue potential; no immediate revenue figure provided but represents a meaningful lifecycle extension.
Risk Factors
- Regulatory delays or restrictions in other geographies for this indication.
- Competition from biosimilars or alternative therapies in development.
- Safety profile could evolve with broader pediatric use.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272191 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 31, 2026
9d ago
|
ANALYST-UPGRADE
| $810.25 $752.29 | ▼ −7.15% | ▼ −7.28% | $611.34 (−24.55%) |
|
May 21, 2026
19d ago
|
Press Release
| $638.53 $600.65 | ▼ −5.93% | ▼ −7.59% | $611.34 (−4.26%) |
|
May 18, 2026
22d ago
|
ANALYST-DOWNGRADE
| $629.34 $632.17 | ▼ −0.45% | ▲ +1.17% | $611.34 (+2.86%) |
|
May 18, 2026
22d ago
|
Press Release
| $629.34 $632.17 | ▲ +0.45% | ▼ −1.17% | $611.34 (−2.86%) |
|
May 16, 2026
25d ago
|
Press Release
| $629.34 $632.17 | ▼ −0.45% | ▲ +1.17% | $611.34 (+2.86%) |
|
May 15, 2026
25d ago
|
Press Release
| $696.20 $638.53 | ▼ −8.28% | ▼ −9.25% | $611.34 (−12.19%) |
|
May 1, 2026
5w ago
|
ANALYST-UPGRADE
| $810.25 $752.29 | ▼ −7.15% | ▼ −7.28% | $611.34 (−24.55%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $744.35 $709.19 | ▼ −4.72% | ▼ −5.12% | $611.34 (−17.87%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $747.15 $729.36 | ▼ −2.38% | ▼ −3.46% | $611.34 (−18.18%) |
|
Apr 13, 2026
8w ago
|
Press Release
| $745.61 $749.26 | ▲ +0.49% | ▼ −2.81% | $611.34 (−18.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access